MT-I vs MT-II
Melanotan I (MT-I) and Melanotan II (MT-II) are related synthetic analogues developed from research into alpha-melanocyte-stimulating hormone (α-MSH). Although both belong to the melanocortin field, they are distinct peptides with different molecular structures and receptor-binding profiles.
MT-I is a linear analogue that remains relatively close to the structure of α-MSH, whereas MT-II is a shorter cyclic analogue. These structural differences influence how the peptides interact with melanocortin receptors and mean that findings involving one should not automatically be applied to the other.
Peptide structures
MT-I is commonly described as the linear α-MSH analogue [Nle4,D-Phe7]-α-MSH. Modifications to the natural α-MSH sequence were introduced to increase stability and prolong biological activity compared with the endogenous peptide.
MT-II is structurally different. It is a shorter cyclic peptide in which cyclisation restricts the molecule's shape. This altered conformation affects receptor binding and contributes to MT-II's broader activity across the melanocortin receptor family.
Relationship to alpha-MSH
Both peptides originated from research into α-MSH, an endogenous peptide involved in melanocortin signalling. α-MSH is produced from the precursor protein proopiomelanocortin (POMC) and is particularly associated with signalling through MC1R on melanocytes.
Natural α-MSH is relatively susceptible to enzymatic degradation. Researchers therefore developed synthetic analogues to investigate whether structural changes could produce more stable molecules while retaining melanocortin activity. MT-I and MT-II represent two different approaches arising from this research.
Melanocortin receptors and selectivity
Five melanocortin receptors are recognised: MC1R, MC2R, MC3R, MC4R and MC5R. They are distributed across different tissues and participate in distinct physiological processes.
MC1R is particularly relevant to pigmentation because its activation on melanocytes influences melanogenesis. MT-I has been strongly associated with this area of research. MT-II displays broader agonist activity involving several melanocortin receptor subtypes, including receptors expressed within the central nervous system.
This difference in receptor pharmacology is one of the main reasons MT-I and MT-II should not be treated as interchangeable compounds.
Research history and afamelanotide
Research involving MT-I contributed to the development of afamelanotide, a pharmaceutical α-MSH analogue that subsequently underwent formal clinical development.
Afamelanotide is used as a regulated medicine for a specific indication involving erythropoietic protoporphyria (EPP). Its clinical development provides a substantially different evidence base from that surrounding MT-II.
Evidence obtained using regulated pharmaceutical afamelanotide should not automatically be attributed to independently produced materials labelled Melanotan I, and it should not be transferred to MT-II.
Pigmentation research and human evidence
Pigmentation has been a major focus of melanocortin research because MC1R signalling influences melanocyte activity and melanin production. Both MT-I and MT-II have therefore appeared in research investigating melanocortin-mediated pigmentation.
Human research has also been conducted with melanocortin analogues, but the quality and regulatory context of this evidence differs considerably between compounds. Afamelanotide has undergone formal clinical trials and pharmaceutical development, whereas MT-II has not followed the same regulatory pathway.
Human findings should therefore always be attributed to the exact peptide and formulation investigated rather than broadly to “Melanotan.”
Major scientific differences
The principal differences between MT-I and MT-II involve their structures, receptor pharmacology and development histories.
MT-I is a linear α-MSH analogue and is particularly associated with MC1R and pigmentation research. MT-II is shorter and cyclic and displays broader activity across several melanocortin receptors.
The MT-I research lineage also contributed to the pharmaceutical development of afamelanotide, while MT-II remained primarily an experimental melanocortin compound. These distinctions are important when comparing evidence relating to the two peptides.
Terminology
Melanocortin research contains several overlapping names that can cause confusion. Melanotan I, MT-I and [Nle4,D-Phe7]-α-MSH are closely related terms encountered in the historical literature, while afamelanotide is associated with subsequent pharmaceutical development of this analogue.
Melanotan II and MT-II refer to a separate cyclic melanocortin analogue.
The shared “Melanotan” name therefore indicates a common research history rather than molecular equivalence. Scientific evidence should be traced to the exact compound used in each study.
Frequently asked questions
Are MT-I and MT-II the same peptide?
No. They are related α-MSH analogues but have different molecular structures and receptor-binding characteristics.
Which peptide is cyclic?
MT-II is cyclic, whereas MT-I is a linear peptide analogue.
Are both related to alpha-MSH?
Yes. Both originated from research into α-MSH and the melanocortin receptor system.
Do MT-I and MT-II interact with the same receptors?
Their receptor activity overlaps, but their pharmacological profiles differ. MT-II has broader activity across several melanocortin receptor subtypes.
Is afamelanotide MT-II?
No. Afamelanotide developed from the MT-I research lineage and is distinct from MT-II.
Can evidence for MT-I be applied to MT-II?
Not automatically. Differences in structure and receptor pharmacology mean evidence for each compound needs to be evaluated independently.
Scientific references
Scientific literature comparing MT-I and MT-II should be evaluated according to the exact peptide, formulation, receptor assay, experimental model and endpoint studied. Research involving pharmaceutical afamelanotide should also be distinguished from studies involving MT-II or independently produced materials labelled Melanotan I.